Skip to content
BiologicalX

Comparison

Modafinil vs Testosterone

Side-by-side of Modafinil and Testosterone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Modafinil

  • FDA approved in 1998 for narcolepsy, with later additions for shift-work sleep disorder and OSA residual sleepiness
  • Schedule IV controlled substance in the US; prescription-only in EU, UK, Australia
  • Increases wakefulness via weak dopamine reuptake inhibition plus histaminergic, noradrenergic, and orexinergic activation
  • Long half-life of 12 to 15 hours requires morning dosing to avoid sleep disruption
  • Modest cognitive enhancement signal in non-sleep-deprived adults at 100 to 200 mg (Battleday meta-review 2015)
  • Substantial CYP3A4 induction reduces hormonal contraceptive efficacy; barrier methods recommended

Testosterone

  • Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
  • Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
  • TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
  • Schedule III controlled substance in US; WADA banned in sport
  • Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
  • Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect

Side-by-side

Attribute Modafinil Testosterone
Category pharmaceutical hormone
Also known as Provigil, Modalert, Modvigil, diphenylmethylsulfinyl-acetamide TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim
Half-life (hr) 13 192
Typical dose (mg) 200 150
Dosing frequency daily, morning weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet)
Routes oral intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral
Onset (hr) 1 24
Peak (hr) 3 72
Molecular weight 273.35 288.42
Molecular formula C15H15NO2S C19H28O2
Mechanism Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake-promoting systems. Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects.
Legal status Schedule IV (US); prescription-only globally; not a supplement Schedule III controlled substance (US); WADA banned
WADA status banned banned
DEA / Rx Schedule IV Schedule III
Pregnancy Not recommended Category X; contraindicated in pregnancy (virilizing effect on female fetus)
CAS 68693-11-8 58-22-0
PubChem CID 4236 6013
Wikidata Q422968 Q150726

Safety profile

Modafinil

Common side effects

  • headache
  • nausea
  • anxiety
  • insomnia (with late-day dosing)
  • dry mouth
  • mild blood pressure elevation

Contraindications

  • recent myocardial infarction
  • unstable angina
  • left ventricular hypertrophy
  • significant arrhythmia
  • history of Stevens-Johnson syndrome
  • psychotic disorders
  • pregnancy
  • concurrent MAOI use

Interactions

  • hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
  • cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
  • warfarin: CYP2C9 inhibition raises INR(moderate)
  • phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
  • MAOIs: potential hypertensive reaction(major)
  • classical stimulants (amphetamine, methylphenidate): additive cardiovascular and sleep-disruption effects(moderate)

Testosterone

Common side effects

  • erythrocytosis
  • acne
  • oily skin
  • fluid retention
  • increased body hair
  • fertility suppression
  • injection-site reactions

Contraindications

  • active prostate cancer
  • active breast cancer
  • untreated severe sleep apnea
  • untreated severe BPH
  • uncontrolled heart failure
  • polycythemia at baseline

Interactions

  • warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
  • insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
  • 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
  • aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)

Which Should You Take?

Modafinil and Testosterone score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.

  • If your priority is wakefulness, pick Modafinil.
  • If your priority is focus or working memory, pick Modafinil.
  • If your priority is hormonal optimization, pick Testosterone.
  • If your priority is sexual function, pick Testosterone.

Edge case: Testosterone is contraindicated in pregnancy; Modafinil is the safer pick if that applies.

Default choice: either is defensible. Modafinil edges out on goal breadth + legal accessibility; Testosterone is the right call if your priority sits in the goals listed above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Modafinil and Testosterone?

Modafinil and Testosterone differ in category (pharmaceutical vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Modafinil or Testosterone?

Modafinil half-life is 13 hours; Testosterone half-life is 192 hours.

Can you stack Modafinil with Testosterone?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper